These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18209781)

  • 1. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
    Joy T; Walsh G; Tokmakejian S; Van Uum SH
    Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Sweet Dreams', 'Happy Days' and elevated 24-h urine 5-hydroxyindoleacetic acid excretion.
    Hallin ML; Mahmoud K; Viswanath A; Gama R
    Ann Clin Biochem; 2013 Jan; 50(Pt 1):80-2. PubMed ID: 23086978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
    Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S; Takahashi R; Masumura I; Miike A
    Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
    Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
    J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S; Takahashi R; Masumura I; Miike A
    Folia Psychiatr Neurol Jpn; 1976; 30(4):463-73. PubMed ID: 1088138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors.
    Zuetenhorst JM; Korse CM; Bonfrer JM; Peter E; Lamers CB; Taal BG
    Clin Chem; 2004 Sep; 50(9):1634-9. PubMed ID: 15247155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary serotonin in the diagnosis of carcinoid tumors.
    Feldman JM
    Clin Chem; 1986 May; 32(5):840-4. PubMed ID: 2421946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary free cortisol excretion in patients with hyperserotoninaemia from the carcinoid syndrome.
    Feldman JM
    Clin Endocrinol (Oxf); 1979 Nov; 11(5):541-8. PubMed ID: 316372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin metabolism in patients with carcinoid tumors: incidence of 5-hydroxytryptophan-secreting tumors.
    Feldman JM
    Gastroenterology; 1978 Dec; 75(6):1109-14. PubMed ID: 309417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression.
    Amamoto T; Sarai K
    Hiroshima J Med Sci; 1976 Sep; 25(2-3):135-40. PubMed ID: 1088369
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-hydroxytryptamine metabolism in sheep.
    Bartlet AL
    Br J Pharmacol; 1971 Jun; 42(2):273-80. PubMed ID: 5314578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.
    Keszthelyi D; Troost FJ; Jonkers DM; van Eijk HM; Lindsey PJ; Dekker J; Buurman WA; Masclee AA
    Aliment Pharmacol Ther; 2014 Aug; 40(4):392-402. PubMed ID: 24943480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
    Magnussen I; Jensen TS; Rand JH; Van Woert MH
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin.
    Kema IP; de Vries EG; Schellings AM; Postmus PE; Muskiet FA
    Clin Chem; 1992 Apr; 38(4):534-40. PubMed ID: 1373675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
    Jacobsen MB; Hanssen LE
    J Intern Med; 1995 Mar; 237(3):269-75. PubMed ID: 7534331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
    Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
    Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of 5-hydroxyindole derivates after administration of L-5-hydroxytryptophan ethyl ester.
    Korf J; Sebens JB; Venema K; van Praag HM
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):171-82. PubMed ID: 968174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.